• There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • The mediannumber of chemotherapy regimens was 2 after tositumomab/iodine-131 tositumomaband prior to HSCT (range: 1-4). (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • Hematopoietic stem cell transplantation (HSCT) results in the alteration of several components of the immune system. (medscape.com)
  • Patients who undergo HSCT experience a sequential suppression of host defenses, resulting in varying infectious risk at different phases of the transplantation process. (medscape.com)
  • Although outcomes after HSCT have improved markedly since transplants were first utilized, infection remains an important source of morbidity. (medscape.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • One needs to differentiate between tandem transplants, a planned sequence of two high dose treatments with HSCT salvage, and a second transplant, an approach of consolidating the first autologous HSCT with another HSCT ONLY if the first one appears partially effective. (cancertreatmenttoday.org)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • The successful application of HSCT for diseases such as leukemia, lymphoma, myeloma, and inherited blood disorders underscored its broad applicability in clinical practice (Snowden et al. (revistadehematologia.org.mx)
  • The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. (mayo.edu)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem-cell transplantation follows (if the patient is considered eligible for HDCT and ASCT). (wikipedia.org)
  • The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. (elsevierpure.com)
  • Myeloablation is accomplished by high-dose chemotherapy with or without irradiation. (medscape.com)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • All patients received multi-agent induction chemotherapy for 6 cycles, including an initial 2 cycles of high-dose cyclophosphamide plus topotecan followed by blood stem cell collection. (oncologynurseadvisor.com)
  • High-dose cyclophosphamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) was then used to mobilize stem cells prior to peripheral blood stem cell (PBSC) collection. (cancertreatmenttoday.org)
  • After stem cell collection, EDAP (etoposide, dexamethasone, cytarabine, cisplatin) was given to enhance reduction of tumor cells prior to high-dose therapy (melphalan 200 mg/m²) and autologous transplant. (cancertreatmenttoday.org)
  • The second course of high-dose therapy and transplant was performed 3 to 6 months later. (cancertreatmenttoday.org)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity [31]. (slideshare.net)
  • At this year's ASH meeting, data from the Phase 3 TOURMALINE-MM3 trial, evaluating the effect of NINLARO (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT), will be presented for the first time during an oral session on Sunday, December 2 at 7:30 a.m. (covaipost.com)
  • These are intensive chemotherapy regimens that, on one level, serve to identify patients who can tolerate such therapy, and they may offer potent cytoreduction, with the quality of remission being the biggest predictor of success with subsequent high-dose chemotherapy and autologous stem cell transplantation. (expertperspectives.com)
  • In this type of transplant, the patient's own stem cells are collected before the high-dose chemotherapy and/or radiation therapy is given. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are not damaged or diseased, but are being used as a rescue therapy after high-dose chemotherapy or radiation therapy. (vanyahealth.com)
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
  • The team focuses its research on donor types, treatment complications (such as graft-vs-host disease), cytomegalovirus vaccination and regimens designed to reduce the risk of relapse. (lovesorghum.com)
  • His academic interests include protocol development for novel therapeutic agents for stem cell transplant conditioning regimens, management of graft vs. host disease, and lymphoid malignancies. (northwestern.edu)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
  • BACKGROUND: The incorporation of anti-CD38 monoclonal antibodies (mAb) in induction regimens of newly diagnosed transplant-eligible multiple myeloma (MM) patients has been established as a new standard. (bvsalud.org)
  • While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. (biomedcentral.com)
  • Treatment with activated factor 7 and in a patient with multiple myeloma who had received an allogeneic stem cell transplant requiring substantial corticosteroids was given with some clinical improvement immunosuppression. (cdc.gov)
  • in an hyperbilirubinemia and elevation of liver aminotransferases, immunosuppressed patient who received an allogeneic together with diarrhea, abdominal distension, and new stem cell transplant for multiple myeloma. (cdc.gov)
  • Chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. (cancertreatmenttoday.org)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • This procedure is typically used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma, as well as other disorders such as sickle cell anemia and thalassemia. (vanyahealth.com)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • Diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, accounting for more than 30 percent of newly diagnosed cases. (lymphomaindia.com)
  • Approximately 30-40 % of patients with FL will eventually transform to a more aggressive form of lymphoma like Diffuse Large B Cell Lymphoma and may require intensive chemotherapy followed by autologous stem cell transplantation. (lymphomaindia.com)
  • Safety, tolerability, toxicity management, and supportive care are important aspects of patient counseling in the treatment of diffuse large B-cell lymphoma (DLBCL). (expertperspectives.com)
  • Validation of the ΔSUV for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. (canceropole-est.org)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. (biomedcentral.com)
  • The International PTCL project that collected 1314 cases of T/NK-cell lymphomas from 22 institutions worldwide revealed that the most common subtypes worldwide are the nodal T cell lymphomas [ 2 ]. (biomedcentral.com)
  • In the nodal T cell lymphomas, the major subtypes are PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and ALK-negative ALCL. (biomedcentral.com)
  • however, outcomes are poor when PTCL is treated according to strategies established for aggressive B cell lymphomas [ 3 ]. (biomedcentral.com)
  • Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. (u-tokyo-hemat.com)
  • Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. (astct.org)
  • Therefore, in the 1940s, several patients with advanced lymphomas (cancers of certain white blood cells) were given the drug by vein, rather than by breathing the irritating gas. (wikidoc.org)
  • As chemotherapy affects cell division, tumors with high growth fractions (such as acute myelogenous leukemia and the aggressive lymphomas , including Hodgkin's disease ) are more sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing cell division at any time. (wikidoc.org)
  • Malignancies with slower growth rates, such as indolent lymphomas, tend to respond to chemotherapy much more modestly. (wikidoc.org)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • This trial confirmed the results of other trials that demonstrated a substantial incidence of symptomatic hypotension in MM patients in the peri-transplant period following ASCT. (astct.org)
  • Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. (who.int)
  • The research team is working to reduce treatment toxicity and improve patient outcomes using leading-edge research to advance hematopoietic stem cell transplant methods. (lovesorghum.com)
  • The aim of this study is to measure the differences in quality of life and mood of hematopoietic stem cell transplant (HCT) patients and their caregivers staying at a hospital hospitality house (HHH), such as the Gift of Life Transplant House, the Help in Healing Home, and the Gabriel House of Care versus staying at a hotel/rental apartment or house. (mayo.edu)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Independent origins of fetal liver haematopoietic stem and progenitor cells. (u-tokyo-hemat.com)
  • Fanconi anemia (FA) is an inherited disorder affecting DNA repair in hematopoietic (blood) stem and progenitor cells (HSPCs) from the bone marrow. (fredhutch.org)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • The transplant procedure requires the harvesting of hematopoietic stem cells from a donor. (medscape.com)
  • In autologous transplantation, the donor and recipient is the same individual. (medscape.com)
  • When the donor is someone other than the recipient, the procedure is described as allogeneic transplantation. (medscape.com)
  • In syngeneic transplants, the donor is the identical twin of the recipient. (medscape.com)
  • Allogeneic transplants are further categorized by the degree of human leukocyte antigen (HLA) match between the donor and recipient. (medscape.com)
  • In such cases, the transplantation procedure is prioritized during the early stages, provided a suitable donor is identified. (medistateinternational.com)
  • The decision to proceed with stem cell transplantation for these conditions hinges on a comprehensive evaluation of the disease's course, severity, donor-related attributes, and procedural risks. (medistateinternational.com)
  • The success of stem cell transplantation pivots on the identification of a donor possessing either a fully-matched or partially-matched tissue group with the patient. (medistateinternational.com)
  • The high doses of therapy lead to destruction of patient's marrow and immune system, which is then replaced by healthy marrow from self (autologous) or donor (allogeneic) hematopoietic stem cells that have been harvested from bone marrow or peripheral blood before therapy. (lovesorghum.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • Microsporidiosis peripheral blood SCT (with a single mismatch at the DRB1 locus) from an unrelated donor. (cdc.gov)
  • Patient the initial transplant, the patient received a second SCT from the same donor after a conditioning regimen with antithymocyte globulin. (cdc.gov)
  • This way of making iPSCs from adult cells circumvents the need to destroy an embryo from living donor. (bmrat.org)
  • However, HLA-identical sibling stem cell infusions in ADA-SCID result in some donor stem cell engraftment and long-term thymopoiesis. (frontiersin.org)
  • She received a matched sibling donor unconditioned stem cell infusion at 16 months of age. (frontiersin.org)
  • There was 93% donor T-lymphocytes, 20% donor B-lymphocytes, and 5% donor myeloid cells, indicative of some donor stem cell engraftment. (frontiersin.org)
  • When tested on healthy donor bone marrow cells, the lineage depleted cells and CD34 + -enriched cells were transduced with similar efficiencies by the FANCA-carrying viral vector. (fredhutch.org)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • In this type of transplant, stem cells are taken from a donor (usually a close relative or sibling) and given to the patient. (vanyahealth.com)
  • Haploidentical transplant, also known as half-matched transplant, is a type of allogeneic transplant where the donor and the recipient are not a perfect match but share one haplotype (half of the genetic material) in common. (vanyahealth.com)
  • Cord blood transplants are an alternative to using stem cells from a matched adult donor. (vanyahealth.com)
  • Both haploidentical BMT and cord blood transplant are considered alternative options for patients who do not have a suitable matched donor. (vanyahealth.com)
  • They come with their own set of risks and benefits, and the decision to use them will depend on the patient's specific circumstances and the availability of a suitable cord blood unit or haploidentical donor. (vanyahealth.com)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
  • In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. (wikipedia.org)
  • four othersreceived a reduced-intensity regimen consisting of fludarabine (Fludara),busulfan (Myleran), tacrolimus (Prograf), mycophenolate mofetil (CellCept), and4 Gy of total lymphoid radiation. (cancernetwork.com)
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
  • STUDY DESIGN AND METHODS: From May 2020 till September 2022, we retrospectively reviewed patients receiving anti-CD38 mAb-based induction therapy followed by stem cell mobilization either in a steady-state protocol (SSM) using 10 µg/kg granulocyte colony-stimulating factor (G-CSF) for 5 days or in a chemotherapy-based protocol (CM) using 1-4 g/m2 cyclophosphamide and G-CSF. (bvsalud.org)
  • Blood Adv. 2022 Mar 8;6(5):1585-1597. (u-tokyo-hemat.com)
  • A liver biopsy and paracentesis were transplant (SCT), she experienced a relapse of disease performed on day 85. (cdc.gov)
  • Some patients may not respond to chemotherapy at all while few patients respond initially but later on relapse. (lymphomaindia.com)
  • Non-Relapse Mortality after CAR T-Cell therapy for Large B-Cell Lymphoma: A LYSA Study from the DESCAR-T Registry. (canceropole-est.org)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • However, the optimal strategy of stem cell mobilization in this context is not yet clear. (bvsalud.org)
  • The patients were evaluated based on PBSC mobilization and collection parameters, including overall collection results, CD34 + cell levels in peripheral blood, leukapheresis (LP) delays, overall number of LP sessions, and the rate of rescue mobilization with plerixafor. (biomedcentral.com)
  • However, during stem cell mobilization and -collection, no study-specific therapeutic intervention was performed. (biomedcentral.com)
  • PBSC mobilization should be performed after induction therapy to ensure collection of a sufficient number of cells. (biomedcentral.com)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • 1989). Hematopoietic stem cells could be harvested easier from peripheral blood after mobilization with G-CSF (Sheridan et al. (revistadehematologia.org.mx)
  • use of mobilization drugs to decrease HSPC retention in the bone marrow and allow their mobilization to the peripheral blood). (fredhutch.org)
  • This procedure starts with the patient receiving intensive chemotherapy with or without total body irradiation in an attempt to kill all cancerous cells. (lovesorghum.com)
  • We conclude that ex vivo drug response profiling is clinically feasible and has the potential to predict chemotherapy response in individuals with hematologic malignancies beyond clinically established genetic markers. (bvsalud.org)
  • Findings were presented at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) and focused on the subset of patients from the trial who went to transplant in first remission. (oncnursingnews.com)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • Dr. Moreira's clinical practice is focused on hematopoietic stem cell transplantation for hematologic and solid malignancies. (northwestern.edu)
  • Hematopoietic Stem Cell Transplantation for benign and malignant hematologic conditions, both autologous and allogeneic. (northwestern.edu)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • In preparation for receipt of the stem cells, recipients undergo myeloablation to eliminate their own myeloid cells. (medscape.com)
  • To improve isolation and modification of HSPCs as well as their engraftment in the transplant recipients, the authors modified recommendations from the international FA Gene Therapy Working Group. (fredhutch.org)
  • Time trends in risk and risk determinants of non-hodgkin lymphoma in solid organ transplant recipients. (medscape.com)
  • The work of Jean Dausset, whose discovery of the human leukocyte antigen (HLA) system revolutionized our understanding of tissue compatibility for transplantation (Dausset J, 1958). (revistadehematologia.org.mx)
  • Positive data from the TOURMALINE-MM3 trial, the first and only Phase 3 placebo-controlled study evaluating a proteasome inhibitor in this setting, showed that using NINLARO as a post-autologous stem cell transplant maintenance treatment improved progression-free survival over the control arm, highlighting NINLARO's potential use as a maintenance therapy in a patient population where there are currently limited options. (covaipost.com)
  • As explained by Dr. Adair, "our previous work and in research done by others in the field, there has been a clear need to correct the FA defect to elicit engraftment of FA cells. (fredhutch.org)
  • We hope that this study will demonstrate the ability to not only isolate more of this limited stem cell pool from FA patients, but will also render these fewer cells more fit for engraftment. (fredhutch.org)
  • Special advances are achieved in HER-positive tumors using targeted therapy with drugs which suppress the tumor cell growth factors (trastuzumab, herceptin). (cttjournal.com)
  • Drugs affect "younger" tumors (i.e. more differentiated) more effectively, because mechanisms regulating cell growth are usually still preserved. (wikidoc.org)
  • With succeeding generations of tumor cells, differentiation is typically lost, growth becomes less regulated, and tumors become less responsive to most chemotherapeutic agents. (wikidoc.org)
  • While the origin of these tumors is still not definitively known, the two theories with the most support suggest that these tumors arise from a primitive cell derived either from an embryologic tissue called the neural crest, or from resident cells in the body (called mesenchymal stem cells) that have a capability to become one of a variety of tissue types. (sarcomahelp.org)
  • Tumors in the Ewing's family of sarcomas are made of primitive cells, which are cells that haven't yet decided what type of cell they are. (sarcomahelp.org)
  • While alternative therapeutic techniques persist, bone marrow/peripheral stem cell transplantation emerges as a transformative option, particularly when other methods display limited efficacy. (medistateinternational.com)
  • Recently, stem cells are being engineered to carry therapeutic reagents to target tumor sites. (bmrat.org)
  • With the presentation of data from two Phase 3 clinical trials as well as our pipeline, Takeda continues to grow the body of evidence for new therapeutic options that improve the way in which we treat blood cancer patients," said Christophe Bianchi, M.D., President, Takeda Global Oncology Business Unit. (covaipost.com)
  • This could re-open the door for up-and-coming, non-chemotherapy based conditioning regimens currently under study to improve the therapeutic potential of gene therapy for the many FA patients who do not have suitable allogeneic donors available. (fredhutch.org)
  • We confirmed the predictive value of ex vivo response to chemotherapy in a validation cohort of 95 individuals with acute myeloid leukemia treated with daunorubicin and cytarabine. (bvsalud.org)
  • Regardless of prior allogeneic hematopoietic cell transplantation (allo-HCT) or pre-allo minimal residual disease (MRD) status, patients with newly diagnosed, FLT3 -ITD-positive acute myeloid leukemia (AML) in their first complete remission (CR1) were found to achieve superior overall survival (OS) when quizartinib (Vanflyta) was added to their standard intensive induction and consolidation therapy, according to data from post-hoc analyses of the phase 3 QuANTUM-First study (NCT02668653). (oncnursingnews.com)
  • Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML). (apbmt.org)
  • Hematopoietic cell transplantation (HCT) is an effective treatment in patients with acute myeloid leukemia (AML). (apbmt.org)
  • In the single autologous HCT arm, 129 of the 179 patients were subsequently given dinutuximab, an anti-GD2 monoclonal antibody, plus cytokine immunotherapy after single transplant consolidation therapy. (oncologynurseadvisor.com)
  • Results showed that 3-year event-free survival was 48.4% ± 3.8% with single autologous HCT compared with 61.4% ± 3.7% with tandem autologous HCT ( P =.0081). (oncologynurseadvisor.com)
  • Preliminary results of several randomized trials comparing tandem and single autologous transplants, which have not been followed as long, have also shown superior event-free survival with the tandem regimen in most studies. (cancertreatmenttoday.org)
  • The deleterious effects of mutated IKZF1 also prevailed in patients who underwent allogeneic hematopoietic stem cell transplantation (n = 519) in both univariable and multivariable models. (bvsalud.org)
  • A total of 83 patients underwent autologous transplantation and all were engrafted. (bvsalud.org)
  • The purity of the CD34 + cells was higher than for the first two patients who underwent direct CD34 enrichment, and the transduction efficiency was similar. (fredhutch.org)
  • In patients who underwent transplant in first remission, there was longer survival in those treated with quizartinib than those on the placebo arm of the study. (oncnursingnews.com)
  • A study by Salles et al determined that correlations between specific biomarkers and the international prognostic index (IPI) score demonstrate that IPI remains the best available index in patients with DLBCL treated with rituximab and chemotherapy. (medscape.com)
  • Most important aspect of therapy is anti CD20 antibody, the Rituximab, which is a kind of immunotherapy or targeted therapy and attacks the CD20 antigen on the cancer cells. (lymphomaindia.com)
  • Rituximab should be combined with the chemotherapy for more efficient cancer cell kill. (lymphomaindia.com)
  • Common combination regimens include: Rituximab with CVP regime (R-CVP), R-CHOP, R-Bendamustine. (lymphomaindia.com)
  • Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study. (canceropole-est.org)
  • Autologous transplantation is feasible when the patient's bone marrow is normal and there are no relevant genetic conditions. (medscape.com)
  • In cases where such donors are not available, the process can extend to non-related donors or even a patient's own cells, demonstrating the flexibility and innovation inherent in this field. (medistateinternational.com)
  • It permits the administration of exceedingly high doses of chemotherapy, a practice that becomes viable due to the subsequent infusion of the patient's own stem cells. (medistateinternational.com)
  • This twofold approach not only harnesses the power of potent chemotherapy but also safeguards against bone marrow deficiency by replenishing the patient's stem cell count following the chemotherapy phase. (medistateinternational.com)
  • After the chemotherapy and radiation therapy, the stored stem cells are thawed and returned to the patient's body. (vanyahealth.com)
  • The donor's cells are a genetic match to the patient's, which reduces the risk of rejection. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are damaged or diseased. (vanyahealth.com)
  • The donor's stem cells will engraft in the patient's bone marrow and start producing new blood cells. (vanyahealth.com)
  • The donor's cells are not as well matched to the patient's cells as in a standard allogeneic transplant, which increases the risk of complications such as graft-versus-host disease (GVHD) and graft rejection. (vanyahealth.com)
  • The main advantage is that cord blood cells are less mature than adult stem cells, which makes it less likely for the patient's immune system to reject the transplant. (vanyahealth.com)
  • However, cord blood units often have fewer stem cells than a bone marrow or peripheral blood transplant, which can increase the time it takes for the patient's blood counts to recover. (vanyahealth.com)
  • This occurs when the donated cells attack the patient's own cells in case of allogeneic transplant. (vanyahealth.com)
  • This occurs when the donated cells do not engraft or grow properly in the patient's bone marrow. (vanyahealth.com)
  • Donors for allogeneic transplants may be related or unrelated to the recipient. (medscape.com)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • The team has access to a large transplant patient population, rich historical data and a clinical department with a reputation for outstanding transplant outcomes for the past 12 consecutirve years. (lovesorghum.com)
  • Neither pre-transplant clinical characteristics nor transplant characteristics are reliably predictive of GvHD outcomes. (cryostem.org)
  • In clinical studies of patients with high-risk neuroblastoma, Grade 3 peripheral sensory neuropathy occurred in 2% to 9% of patients. (nih.gov)
  • abstract: PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
  • ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. (wikipedia.org)
  • Physicians and scientists work side by side to set standards for stem cell transplantation and improve long-term outcomes for both pediatric and adult patients. (lovesorghum.com)
  • Invited discussant for this abstract Dominique Valteau-Couanet, MD, PhD, head of the pediatric and adolescent oncology department at Institut Gustave Roussy in France, questioned which patients actually benefit from tandem autologous HCT: patients with localized disease and MYCN amplification? (oncologynurseadvisor.com)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • Secondary endpoint analysis revealed that ex vivo resistance to chemotherapeutic drugs predicted chemotherapy treatment failure in vivo. (bvsalud.org)
  • The procedure of bone marrow / peripheral stem cell transplantation serves as a pivotal treatment avenue for patients contending with a spectrum of medical challenges. (medistateinternational.com)
  • Often, conventional medical treatment options are limited, leaving stem cell transplantation as a potential game-changer. (medistateinternational.com)
  • The study further demonstrated that tandem autologous HCT also benefits patients who received immunotherapy, with a significant difference in 3-year event-free survival between the 2 treatment arms ( P =.0033). (oncologynurseadvisor.com)
  • Another strategy is the incorporation of novel agents, such as thalidomide, Velcade, or Revlimid, into the treatment regimen either before or after transplant. (cancertreatmenttoday.org)
  • Novel targeted therapies and combination chemotherapies are required for the treatment of patients with PTCL. (biomedcentral.com)
  • This review summarizes the currently available approaches for the treatment of PTCL with an emphasis on potential new agents, including the role of stem cell transplantation. (biomedcentral.com)
  • Stem cells are not only widely used for regenerative medicine, but are also considered as a useful tool for cancer treatment. (bmrat.org)
  • Cancer vaccines based on the knowledge of cancer stem cells have been studied and applied for cancer treatment. (bmrat.org)
  • This re- view discusses stem cell applications in transplantation, stem cell-based carriers, induced-pluripotent stem cells, can- cer stem cells, and potential of stem cells engineering to revolutionize cancer treatment. (bmrat.org)
  • 1992). Since then, hematopoietic stem cells, with their unique ability to differentiate into various blood cell types, have proven to be a revolutionary tool in the treatment of numerous hematological disorders. (revistadehematologia.org.mx)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • Previously in July 2023, the FDA granted approval to the combination of quizartinib and standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly-diagnosed, FLT3 -ITD-positive AML based on published findings from QuANTUM-First. (oncnursingnews.com)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • The safety, tolerability, and toxicity management of therapies for DLBCL are part and parcel with efficacy in considering selection among treatment regimens. (expertperspectives.com)
  • Chemotherapy , in its most general sense, refers to treatment of disease by chemicals that kill cells, specifically those of micro-organisms or cancer . (wikidoc.org)
  • In popular usage, it usually refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a standardized treatment regimen . (wikidoc.org)
  • Other uses of cytostatic chemotherapy agents (including the ones mentioned below) are the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and the suppression of transplant rejections (see immunosuppression and DMARDs ). (wikidoc.org)
  • However, some drugs have a better side-effect profile than others, enabling doctors to adjust treatment regimens to the advantage of patients in certain situations. (wikidoc.org)
  • PR), very good partial response (VGPR), complete response (CR) or stringent CR (sCR) rate differ with respect to treatment regimen. (clinicaltrialsgps.com)
  • progression on treatment or within 60 days of stopping a bortezomib- or carfilzomib-based regimen as last line of therapy. (who.int)
  • Transplants from HLA-matched siblings are associated with a lower risk of GVHD and faster recovery of the recipient's immune system following transplantation. (medscape.com)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • For a long time, stem cells have been utilized to renew the immune system for radiation or chemo- therapy treated patients. (bmrat.org)
  • 1957). This pioneering work laid the foundation for the exploration of hematopoietic stem cells and their role in treating diseases of the blood and immune system. (revistadehematologia.org.mx)
  • At the time they performed the first transplants surprisingly little was known about hematopoietic stem cells, immune responses to transplants or the complex human leucocyte antigen system. (revistadehematologia.org.mx)
  • As a consequence, blood cell counts are very low in patients and the immune system is severely weakened. (fredhutch.org)
  • Unfortunately, scientists have yet to identify specific features of malignant and immune cells that would make them uniquely targetable (barring some recent examples, such as the Philadelphia chromosome as targeted by imatinib ). (wikidoc.org)
  • Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. (clinicaltrialsgps.com)
  • Additionally, the positive data from the ECHELON-2 trial demonstrated that in patients with previously untreated CD30-positive peripheral T-cell lymphoma, ADCETRIS in combination with chemotherapy was superior to the control arm for progression-free survival and overall survival, representing an important milestone for ADCETRIS as a potential therapy in this setting where standard of care has not changed in several decades. (covaipost.com)
  • Radioimmunotherapy (RIT) alone or in combination with chemotherapy: Two radioimmunotherapy drugs are commercially available: Iodine 131 tositumomab (Bexxar) and Y90 ibritumomab tiuxetan (Zevalin). (lymphomaindia.com)
  • CONCLUSIONS: Stem cell collection in patients undergoing anti-CD38-based induction therapy is feasible with either CM or SSM, although SSM more frequently requires plerixafor. (bvsalud.org)
  • Patients treated with isatuximab-RVd (six cycles) had lower numbers of collected stem cells compared to those receiving RVd (six cycles) induction (8.8 × 10 6 /kg bw versus 9.7 × 10 6 /kg bw, p = 0.801), without experiencing significant delays in LP or increased numbers of LP sessions in a multivariable logistic regression analysis. (biomedcentral.com)
  • This study demonstrates that stem cell collection is feasible after prolonged induction with isatuximab-RVd without collection failures and might be further explored as induction therapy. (biomedcentral.com)
  • The Total Therapy I regimen included induction therapy with 3 cycles of VAD (vincristine, doxorubicin, dexamethasone). (cancertreatmenttoday.org)
  • Efforts to overcome chemotherapy resistance by including multidrug resistance modifiers (e.g., cyclosporin or its analogue PSC 833) in the induction schedule have as yet not met with reproducible success in prospective comparative studies. (ashpublications.org)
  • Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. (shengsci.com)
  • abstract: PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). (shengsci.com)
  • Collection failures, defined as the inability to collect three sufficient PBSC transplants, were rare ( n = 3, 2%), with no occurrences in the isatuximab-RVd and elotuzumab-RVd groups. (biomedcentral.com)
  • In cases of unrelated HCT, PBSC transplantation (PBSCT) still comprises only a very small percentage, which reflects the fact that unrelated PBSCT did not come into use in Japan until 2010. (apbmt.org)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • [18] CLLs are, in virtually all cases, preceded by a particular subtype of monoclonal B-cell lymphocytosis (MBL). (wikipedia.org)
  • A tandem autologous transplant, also known as a double autologous transplant, requires the patient to undergo two planned autologous stem cell transplants within 6 months. (cancertreatmenttoday.org)
  • It appears that in patients with poor prognostic features, outcome is not improved with tandem transplants, so additional strategies need to be evaluated in this patient population. (cancertreatmenttoday.org)
  • When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. (rochester.edu)
  • We report a patient with PNP deficiency, who received HLA-identical sibling marrow without chemotherapy because of disseminated cytomegalovirus (CMV) infection. (frontiersin.org)
  • The patient was viremic with CMV detected in blood and CSF by PCR. (frontiersin.org)
  • At 4 years of age and 29 months post-transplant, the patient demonstrated normal T-lymphocyte and natural killer cell numbers. (frontiersin.org)
  • The procedure was successfully replicated using mobilized peripheral blood leukapharesis from another FA patient. (fredhutch.org)
  • Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. (shengsci.com)
  • Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. (apbmt.org)